FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Barth Jay						2. Issuer Name and Ticker or Trading Symbol AMICUS THERAPEUTICS, INC. [ FOLD ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner						
(Last) (First) (Middle) C/O AMICUS THERAPEUTICS, INC. 1 CEDAR BROOK DRIVE						3. Date of Earliest Transaction (Month/Day/Year) 04/05/2019								X	Chief Medical Officer					
(Street) CRANBURY NJ 08512					_   4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line)	Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
(City) (State) (Zip)							tive Securities Acquired, Disposed of, or Beneficially Owned													
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/N					tion	2A. D Exec if any	eeme		3. Transaction Code (Instr. 8)		4. Securities	Acquired	cquired (A) or O) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 04/05/20					2019	9			M		50,000	A	\$2.	29	179	9,767		D		
Common Stock 04/05/20					2019	.9			S <sup>(1)</sup>		50,000	D	\$14.2	039(2)	129	129,767		D		
Common Stock															:	20			by Daughter	
		-	Table I								posed of, , converti				wned		,	,		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expira	e Exer ation D h/Day/		d 7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		D	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction( (Instr. 4)	lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amo or Num of Shar	ber						
Stock Options (right to	\$2.29	04/05/2019			M			50,000	(	3)	03/03/2024	Common Stock	<sup>n</sup> 50,0	000	\$0.00	18,730		D		

## **Explanation of Responses:**

- 1. The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2019.
- 2. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from \$13.99 to \$14.51. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
- 3. All of the options were fully vested and exercisable as of April 5, 2019.

## Remarks:

/s/ Carol Welch, Attorney-in-

04/08/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.